Immediate Impact
61 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Works of Aibing Xu being referenced
Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.
2021
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Aibing Xu | 82 | 47 | 72 | 10 | 175 | |
| Elena Rota Caremoli | 85 | 57 | 67 | 15 | 211 | |
| Kazuki Maesaka | 132 | 33 | 80 | 12 | 196 | |
| Jiali Chen | 83 | 35 | 54 | 10 | 185 | |
| Wen‐Bin Ding | 63 | 74 | 46 | 11 | 188 | |
| Roger Esteban-Fabró | 68 | 37 | 60 | 7 | 145 | |
| Katsumi Terashita | 74 | 65 | 54 | 8 | 182 | |
| Takashi Mineo | 67 | 36 | 84 | 11 | 161 | |
| Derek-Zhen Xu | 118 | 21 | 88 | 6 | 162 | |
| Dafna Kaufman | 125 | 129 | 89 | 9 | 255 | |
| Kengo Kanayama | 45 | 59 | 43 | 10 | 153 |
All Works
Loading papers...